Topic: Metabolic and Alcohol-Related Dual Liver Injury: Exploring MetALD
A Special Issue of Metabolism and Target Organ Damage
ISSN 2769-6375 (Online)
Submission deadline: 31 Dec 2024
Guest Editor(s)
Prof. Vincent Wai Sun Wong
Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Special Issue Introduction
Background and Rationale:
Metabolic dysfunction (i.e., overweight, obesity, insulin resistance, diabetes, hypertension, or dyslipidemia) and alcohol use are two pivotal factors contributing to liver disease, often co-existing and synergistically worsening liver pathology in susceptible individuals. This Special Issue aims to explore the dual impact of these factors on liver health, specifically focusing on Metabolic Dysfunction and Alcohol-associated Liver Disease (MetALD). Given the rising prevalence of both metabolic dysfunction and unhealthy alcohol use globally, understanding the overlapping mechanisms and outcomes in MetALD is of paramount importance.
Objectives:
- To highlight the latest research on the pathophysiology of MetALD
- To explore diagnostic approaches and potential biomarkers for early detection of dual liver injury
- To evaluate current and emerging therapeutic strategies that address both metabolic dysfunction and alcohol use
- To encourage multidisciplinary collaboration among researchers, clinicians, and public health experts to perform timely reviews on MetALD
Topics Covered:
- Epidemiological trends in MetALD
- Mechanistic insights into how metabolic syndrome and alcohol interact at the molecular and clinical level
- Clinical outcomes and challenges in managing dual liver injury
- Prevention and treatment strategies, including lifestyle interventions, and pharmacotherapy
- Strategies to prevent harmful alcohol intake in steatotic liver disease
- Clinical research highlighting effective management practices for patients with dual liver injury
- Diagnostic tests and assessments of liver injury, with a special focus on whether alcohol consumption may confound the currently used tests
Target Audience:
This issue is intended for hepatologists, gastroenterologists, endocrinologists, researchers in liver disease, healthcare policymakers, and primary care physicians who are on the front lines of treating patients with steatotic liver disease.
Metabolic dysfunction (i.e., overweight, obesity, insulin resistance, diabetes, hypertension, or dyslipidemia) and alcohol use are two pivotal factors contributing to liver disease, often co-existing and synergistically worsening liver pathology in susceptible individuals. This Special Issue aims to explore the dual impact of these factors on liver health, specifically focusing on Metabolic Dysfunction and Alcohol-associated Liver Disease (MetALD). Given the rising prevalence of both metabolic dysfunction and unhealthy alcohol use globally, understanding the overlapping mechanisms and outcomes in MetALD is of paramount importance.
Objectives:
- To highlight the latest research on the pathophysiology of MetALD
- To explore diagnostic approaches and potential biomarkers for early detection of dual liver injury
- To evaluate current and emerging therapeutic strategies that address both metabolic dysfunction and alcohol use
- To encourage multidisciplinary collaboration among researchers, clinicians, and public health experts to perform timely reviews on MetALD
Topics Covered:
- Epidemiological trends in MetALD
- Mechanistic insights into how metabolic syndrome and alcohol interact at the molecular and clinical level
- Clinical outcomes and challenges in managing dual liver injury
- Prevention and treatment strategies, including lifestyle interventions, and pharmacotherapy
- Strategies to prevent harmful alcohol intake in steatotic liver disease
- Clinical research highlighting effective management practices for patients with dual liver injury
- Diagnostic tests and assessments of liver injury, with a special focus on whether alcohol consumption may confound the currently used tests
Target Audience:
This issue is intended for hepatologists, gastroenterologists, endocrinologists, researchers in liver disease, healthcare policymakers, and primary care physicians who are on the front lines of treating patients with steatotic liver disease.
Submission Deadline
31 Dec 2024
Submission Information
For Author Instructions, please refer to https://www.oaepublish.com/mtod/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=mtod&SpecialIssueId=mtod240529
Submission Deadline: 31 Dec 2024
Contacts: Jennifer Lee, Assistant Editor, jennifer@mtodjournal.net
